Rani Therapeutics (RANI) Stock Forecast, Price Target & Predictions
RANI Stock Forecast
Rani Therapeutics stock forecast is as follows: an average price target of $15.67 (represents a 498.09% upside from RANI’s last price of $2.62) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
RANI Price Target
The average price target for Rani Therapeutics (RANI) is $15.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $9.00. This represents a potential 498.09% upside from RANI's last price of $2.62.
RANI Analyst Ratings
According to 4 Wall Street analysts, Rani Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RANI stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rani Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 24, 2024 | Annabel Samimy | Stifel Nicolaus | $10.00 | $4.11 | 143.31% | 281.68% |
| Mar 27, 2024 | Edward Nash | Canaccord Genuity | $9.00 | $3.18 | 183.02% | 243.51% |
| Jun 13, 2022 | Andreas Argyrides | Wedbush | $28.00 | $9.40 | 197.87% | 968.70% |
The latest Rani Therapeutics stock forecast, released on Jun 24, 2024 by Annabel Samimy from Stifel Nicolaus, set a price target of $10.00, which represents a 143.31% increase from the stock price at the time of the forecast ($4.11), and a 281.68% increase from RANI last price ($2.62).
Rani Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $10.00 | $9.50 |
| Last Closing Price | $2.62 | $2.62 | $2.62 |
| Upside/Downside | -100.00% | 281.68% | 262.60% |
In the current month, the average price target of Rani Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rani Therapeutics's last price of $2.62. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 01, 2024 | Oppenheimer | - | Outperform | Initialise |
| Jun 12, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 27, 2024 | Canaccord Genuity | Buy | Buy | Hold |
Rani Therapeutics's last stock rating was published by H.C. Wainwright on Aug 16, 2024. The company gave RANI a "Buy" rating, the same as its previous rate.
Rani Therapeutics Financial Forecast
Rani Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.96M |
| Avg Forecast | - | - | - | - | - | - | - | $108.33K | $130.00K | $130.00K | $325.00K | $162.50K | $630.00K | $490.00K |
| High Forecast | - | - | - | - | - | - | - | $108.33K | $130.00K | $130.00K | $325.00K | $162.50K | $630.00K | $490.00K |
| Low Forecast | - | - | - | - | - | - | - | $108.33K | $130.00K | $130.00K | $325.00K | $162.50K | $630.00K | $490.00K |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00% |
Rani Therapeutics's average Quarter revenue forecast for Sep 21 based on 0 analysts is $630.00K, with a low forecast of $630.00K, and a high forecast of $630.00K. RANI's average Quarter revenue forecast represents a -67.87% decrease compared to the company's last Quarter revenue of $1.96M (Jun 21).
Rani Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $-16.66M | $-15.82M | $-15.69M | $-13.65M | $5.88M | $-2.88M | $-5.19M |
| Avg Forecast | - | - | - | - | - | - | - | $-21.67K | $-32.01M | $-9.69M | $-65.00K | $-32.50K | $-34.23M | $-98.00K |
| High Forecast | - | - | - | - | - | - | - | $-21.67K | $-25.60M | $-7.75M | $-65.00K | $-32.50K | $-27.38M | $-98.00K |
| Low Forecast | - | - | - | - | - | - | - | $-21.67K | $-38.41M | $-11.63M | $-65.00K | $-32.50K | $-41.08M | $-98.00K |
| Surprise % | - | - | - | - | - | - | - | 769.18% | 0.49% | 1.62% | 210.06% | -181.05% | 0.08% | 52.93% |
0 analysts predict RANI's average Quarter EBITDA for Mar 22 to be $-65.00K, with a high of $-65.00K and a low of $-65.00K. This is -101.10% lower than Rani Therapeutics's previous annual EBITDA (Dec 21) of $5.88M.
Rani Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | $-17.34M | $-16.21M | $-15.97M | $-13.83M | $-13.22M | $-3.14M | $-5.49M |
| Avg Forecast | $-9.74M | $-9.21M | $-10.13M | $-11.58M | $-7.58M | $-7.63M | $-8.83M | $-10.56M | $-3.64M | $-10.06M | $-17.37M | $-13.03M | $-3.89M | $-4.63M |
| High Forecast | $-9.74M | $-9.21M | $-10.13M | $-11.58M | $-7.58M | $-4.16M | $-8.83M | $-10.56M | $-2.91M | $-8.04M | $-17.37M | $-13.03M | $-3.11M | $-4.63M |
| Low Forecast | $-9.74M | $-9.21M | $-10.13M | $-11.58M | $-7.58M | $-9.72M | $-8.83M | $-10.56M | $-4.36M | $-12.07M | $-17.37M | $-13.03M | $-4.67M | $-4.63M |
| Surprise % | - | - | - | - | - | - | - | 1.64% | 4.46% | 1.59% | 0.80% | 1.01% | 0.81% | 1.18% |
Rani Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RANI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Rani Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | $7.10M | $7.24M | $6.32M | $6.19M | $5.95M | $15.82M | $3.46M |
| Avg Forecast | - | - | - | - | - | - | - | $574.68K | $689.62K | $689.62K | $1.72M | $862.03K | $3.34M | $2.60M |
| High Forecast | - | - | - | - | - | - | - | $574.68K | $689.62K | $689.62K | $1.72M | $862.03K | $3.34M | $2.60M |
| Low Forecast | - | - | - | - | - | - | - | $574.68K | $689.62K | $689.62K | $1.72M | $862.03K | $3.34M | $2.60M |
| Surprise % | - | - | - | - | - | - | - | 12.35% | 10.50% | 9.16% | 3.59% | 6.90% | 4.73% | 1.33% |
Rani Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RANI last annual SG&A of $7.10M (Dec 22).
Rani Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | $-0.70 | $-0.66 | $-0.66 | $-0.65 | $-0.68 | $-0.16 | $-0.29 |
| Avg Forecast | $-0.37 | $-0.35 | $-0.39 | $-0.44 | $-0.29 | $-0.29 | $-0.34 | $-0.40 | $-0.52 | $-0.52 | $-0.66 | $-0.49 | $-0.18 | $-0.18 |
| High Forecast | $-0.37 | $-0.35 | $-0.39 | $-0.44 | $-0.29 | $-0.16 | $-0.34 | $-0.40 | $-0.52 | $-0.52 | $-0.66 | $-0.49 | $-0.18 | $-0.18 |
| Low Forecast | $-0.37 | $-0.35 | $-0.39 | $-0.44 | $-0.29 | $-0.37 | $-0.34 | $-0.40 | $-0.52 | $-0.52 | $-0.66 | $-0.49 | $-0.18 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | 1.75% | 1.26% | 1.28% | 0.98% | 1.37% | 0.89% | 1.66% |
According to undefined Wall Street analysts, Rani Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RANI previous annual EPS of $NaN (undefined).
Rani Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SQZ | SQZ Bio | $0.44 | $400.00 | 90809.09% | Buy |
| VIRX | Viracta Therapeutics | $0.24 | $8.00 | 3233.33% | Buy |
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| ALXO | ALX Oncology | $1.91 | $24.50 | 1182.72% | Buy |
| RANI | Rani Therapeutics | $2.62 | $15.67 | 498.09% | Buy |
| VINC | Vincerx Pharma | $0.71 | $4.00 | 463.38% | Buy |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| TRVI | Trevi Therapeutics | $2.95 | $12.00 | 306.78% | Buy |
| CABA | Cabaletta Bio | $4.26 | $16.33 | 283.33% | Buy |
| EYPT | EyePoint Pharmaceuticals | $7.97 | $30.00 | 276.41% | Buy |
| PHVS | Pharvaris | $19.12 | $38.50 | 101.36% | Buy |
| BMEA | Biomea Fusion | $7.08 | $13.67 | 93.08% | Buy |
| LYRA | Lyra Therapeutics | $0.27 | $0.50 | 85.19% | Hold |
| CRVS | Corvus Pharmaceuticals | $4.03 | $7.00 | 73.70% | Buy |
| TYRA | Tyra Biosciences | $20.59 | $25.00 | 21.42% | Buy |
RANI Forecast FAQ
Is Rani Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Rani Therapeutics (RANI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of RANI's total ratings.
What is RANI's price target?
Rani Therapeutics (RANI) average price target is $15.67 with a range of $9 to $28, implying a 498.09% from its last price of $2.62. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Rani Therapeutics stock go up soon?
According to Wall Street analysts' prediction for RANI stock, the company can go up by 498.09% (from the last price of $2.62 to the average price target of $15.67), up by 968.70% based on the highest stock price target, and up by 243.51% based on the lowest stock price target.
Can Rani Therapeutics stock reach $4?
RANI's average twelve months analyst stock price target of $15.67 supports the claim that Rani Therapeutics can reach $4 in the near future.
What are Rani Therapeutics's analysts' financial forecasts?
Rani Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-24.035M (high $-20.565M, low $-26.117M), average SG&A $0 (high $0, low $0), and average EPS is $-0.913 (high $-0.781, low $-0.992). RANI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-40.671M (high $-40.671M, low $-40.671M), average SG&A $0 (high $0, low $0), and average EPS is $-1.545 (high $-1.545, low $-1.545).
Did the RANI's actual financial results beat the analysts' financial forecasts?
Based on Rani Therapeutics's last annual report (Dec 2021), the company's revenue was $2.72M, beating the average analysts forecast of $1.28M by 111.85%. Apple's EBITDA was $-51.51M, beating the average prediction of $-34.361M by 49.91%. The company's net income was $-53.088M, beating the average estimation of $-21.553M by 146.31%. Apple's SG&A was $27.83M, beating the average forecast of $6.8M by 309.12%. Lastly, the company's EPS was $-2.72, beating the average prediction of $-0.851 by 219.62%. In terms of the last quarterly report (Jun 2021), Rani Therapeutics's revenue was $1.96M, beating the average analysts' forecast of $490K by 300.20%. The company's EBITDA was $-5.187M, beating the average prediction of $-97.999K by 5192.91%. Rani Therapeutics's net income was $-5.485M, beating the average estimation of $-4.633M by 18.39%. The company's SG&A was $3.46M, beating the average forecast of $2.6M by 33.11%. Lastly, the company's EPS was $-0.292, beating the average prediction of $-0.176 by 65.65%